{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:40:00Z","timestamp":1792784400531,"version":"4.5.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Intra-Cellular Therapies, Inc., a Johnson & Johson company","id":[{"id":"https:\/\/ror.org\/04qkyeg11","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40263-025-01206-3","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:14:29Z","timestamp":1753280069000},"page":"913-935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. https:\/\/doi.org\/10.1038\/nrdp.2015.67.","journal-title":"Nat Rev Dis Primers"},{"key":"1206_CR2","doi-asserted-by":"publisher","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789\u2013858. https:\/\/doi.org\/10.1016\/s0140-6736(18)32279-7.","DOI":"10.1016\/s0140-6736(18)32279-7"},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195\u2013203. https:\/\/doi.org\/10.1093\/schbul\/sby058.","journal-title":"Schizophr Bull"},{"key":"1206_CR4","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2021","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021."},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41380-023-02138-4","volume":"2023","author":"M Solmi","year":"2019","unstructured":"Solmi M, Seitidis G, Mavridis D, et al. Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the global burden of disease (GBD). Mol Psychiatry. 2019;2023:1\u20139. https:\/\/doi.org\/10.1038\/s41380-023-02138-4.","journal-title":"Mol Psychiatry"},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248\u201371. https:\/\/doi.org\/10.1002\/wps.20994.","journal-title":"World Psychiatry"},{"key":"1206_CR7","doi-asserted-by":"publisher","unstructured":"Chan JKN, Correll CU, Wong CSM, et al. Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis. EClinicalMedicine. 2023;65. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102294.","DOI":"10.1016\/j.eclinm.2023.102294"},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/ndt.S96649","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357\u201373. https:\/\/doi.org\/10.2147\/ndt.S96649.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. NPJ Schizophr. 2022;8:5. https:\/\/doi.org\/10.1038\/s41537-021-00192-x.","journal-title":"NPJ Schizophr"},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u201377. https:\/\/doi.org\/10.2147\/TCRM.S117321.","journal-title":"Ther Clin Risk Manag"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27:1136\u201344. https:\/\/doi.org\/10.1038\/s41380-021-01334-4.","journal-title":"Mol Psychiatry"},{"key":"1206_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","volume":"52","author":"S-M Wang","year":"2016","unstructured":"Wang S-M, Han C, Lee S-J, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 2016;52:159\u201372. https:\/\/doi.org\/10.4068\/cmj.2016.52.3.159.","journal-title":"Chonnam Med J"},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1017\/S0033291722000745","volume":"53","author":"T Kishimoto","year":"2023","unstructured":"Kishimoto T, Hagi K, Kurokawa S, et al. Efficacy and safety\/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med. 2023;53:4064\u201382. https:\/\/doi.org\/10.1017\/S0033291722000745.","journal-title":"Psychol Med"},{"key":"1206_CR14","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","volume":"35","author":"RS McIntyre","year":"2019","unstructured":"McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019;35:1993\u20132005. https:\/\/doi.org\/10.1080\/03007995.2019.1636017.","journal-title":"Curr Med Res Opin"},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","journal-title":"Bipolar Disord"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62:604\u201316. https:\/\/doi.org\/10.1177\/0706743717720448.","journal-title":"Can J Psychiatry"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: A network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21:295\u2013307. https:\/\/doi.org\/10.1002\/wps.20972.","journal-title":"World Psychiatry"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1038\/s41380-023-02298-3","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Cortese S, Vita G, et al. An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders. Mol Psychiatry. 2023;28:3671\u201387. https:\/\/doi.org\/10.1038\/s41380-023-02298-3.","journal-title":"Mol Psychiatry"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","volume":"10","author":"T Pillinger","year":"2023","unstructured":"Pillinger T, Howes OD, Correll CU, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10:860\u201376. https:\/\/doi.org\/10.1016\/S2215-0366(23)00262-6.","journal-title":"Lancet Psychiatry"},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garcia","year":"2016","unstructured":"Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355\u201371. https:\/\/doi.org\/10.1097\/JCP.0000000000000523.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 2","key":"1206_CR22","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","volume":"25","author":"CU Correll","year":"2010","unstructured":"Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry J Assoc Eur Psychiatr. 2010;25(Suppl 2):S12-21. https:\/\/doi.org\/10.1016\/S0924-9338(10)71701-6.","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41380-022-01727-z","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Croatto G, Piva G, et al. Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. Mol Psychiatry. 2023;28:354\u201368. https:\/\/doi.org\/10.1038\/s41380-022-01727-z.","journal-title":"Mol Psychiatry"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-244X-12-20","volume":"12","author":"M Dibonaventura","year":"2012","unstructured":"Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20. https:\/\/doi.org\/10.1186\/1471-244X-12-20.","journal-title":"BMC Psychiatry"},{"key":"1206_CR25","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264\u201378. https:\/\/doi.org\/10.4088\/JCP.16r10832.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17:330\u201340. https:\/\/doi.org\/10.1002\/wps.20579.","journal-title":"World Psychiatry"},{"key":"1206_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2011.143","volume":"18","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18:53\u201366. https:\/\/doi.org\/10.1038\/mp.2011.143.","journal-title":"Mol Psychiatry"},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(08)61764-X.","journal-title":"Lancet"},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339\u201347. https:\/\/doi.org\/10.1002\/wps.20252.","journal-title":"World Psychiatry"},{"key":"1206_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","volume":"24","author":"T Pillinger","year":"2019","unstructured":"Pillinger T, D\u2019Ambrosio E, McCutcheon R, Howes OD. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24:776\u201394. https:\/\/doi.org\/10.1038\/s41380-018-0058-9.","journal-title":"Mol Psychiatry"},{"key":"1206_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163\u201380. https:\/\/doi.org\/10.1002\/wps.20420.","journal-title":"World Psychiatry"},{"key":"1206_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14740338.2021.1983540","volume":"21","author":"S Taub","year":"2022","unstructured":"Taub S, Krivoy A, Whiskey E, Shergill SS. New approaches to antipsychotic medication adherence\u2014Safety, tolerability and acceptability. Expert Opin Drug Saf. 2022;21:517\u201324. https:\/\/doi.org\/10.1080\/14740338.2021.1983540.","journal-title":"Expert Opin Drug Saf"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35:39\u201359. https:\/\/doi.org\/10.1007\/s40263-020-00779-5.","journal-title":"CNS Drugs"},{"key":"1206_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12888-019-2304-3","volume":"19","author":"SJ Kaar","year":"2019","unstructured":"Kaar SJ, Gobjila C, Butler E, et al. Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid. BMC Psychiatry. 2019;19:309. https:\/\/doi.org\/10.1186\/s12888-019-2304-3.","journal-title":"BMC Psychiatry"},{"key":"1206_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1017\/S1092852900026298","volume":"12","author":"CU Correll","year":"2007","unstructured":"Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr. 2007;12:12\u201320. https:\/\/doi.org\/10.1017\/S1092852900026298.","journal-title":"CNS Spectr"},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41398-021-01636-9","volume":"11","author":"L Katona","year":"2021","unstructured":"Katona L, Bitter I, Czobor P. A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: are the results consistent with the findings of randomized controlled trials? Transl Psychiatry. 2021;11:510. https:\/\/doi.org\/10.1038\/s41398-021-01636-9.","journal-title":"Transl Psychiatry"},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","volume":"79","author":"H Taipale","year":"2022","unstructured":"Taipale H, Schneider-Thoma J, Pinz\u00f3n-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiat. 2022;79:210\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3990.","journal-title":"JAMA Psychiat"},{"key":"1206_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102917","volume":"67","author":"K Hatta","year":"2022","unstructured":"Hatta K, Katayama S, Ishizuka T, et al. Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: a one-year follow-up study. Asian J Psychiatr. 2022;67: 102917. https:\/\/doi.org\/10.1016\/j.ajp.2021.102917.","journal-title":"Asian J Psychiatr"},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/schbul\/sbab004","volume":"47","author":"J Lintunen","year":"2021","unstructured":"Lintunen J, Taipale H, Tanskanen A, et al. Long-term real-world effectiveness of pharmacotherapies for schizoaffective disorder. Schizophr Bull. 2021;47:1099\u2013107. https:\/\/doi.org\/10.1093\/schbul\/sbab004.","journal-title":"Schizophr Bull"},{"key":"1206_CR40","doi-asserted-by":"publisher","unstructured":"Kondej M, Stepnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018;19. https:\/\/doi.org\/10.3390\/ijms19103105.","DOI":"10.3390\/ijms19103105"},{"key":"1206_CR41","doi-asserted-by":"publisher","unstructured":"Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094467.","DOI":"10.3390\/ijms22094467"},{"key":"1206_CR42","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","volume":"16","author":"P Li","year":"2016","unstructured":"Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem. 2016;16:3385\u2013403. https:\/\/doi.org\/10.2174\/1568026616666160608084834.","journal-title":"Curr Top Med Chem"},{"key":"1206_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","volume":"132","author":"MC Lobo","year":"2022","unstructured":"Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324\u201361. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.11.032.","journal-title":"Neurosci Biobehav Rev"},{"key":"1206_CR44","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704.","journal-title":"Neuropharmacology"},{"key":"1206_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/wps.21056","volume":"22","author":"CU Correll","year":"2023","unstructured":"Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023;22:48\u201374. https:\/\/doi.org\/10.1002\/wps.21056.","journal-title":"World Psychiatry"},{"key":"1206_CR46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.0508e14","volume":"69","author":"PF Buckley","year":"2008","unstructured":"Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69:4\u201317.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR47","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","volume":"57","author":"MC Mauri","year":"2018","unstructured":"Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57:1493\u2013528. https:\/\/doi.org\/10.1007\/s40262-018-0664-3.","journal-title":"Clin Pharmacokinet"},{"key":"1206_CR48","unstructured":"Caplyta. Prescribing information. Intra-Cellular Therapies Inc.; 2023."},{"key":"1206_CR49","unstructured":"Vraylar. Prescribing information. Allergan; 2019."},{"key":"1206_CR50","unstructured":"Lybalvi. Prescribing information. Alkermes Inc.; 2021."},{"key":"1206_CR51","unstructured":"Latuda. Prescribing information. Sunovion Pharmaceuticals Inc.; 2019."},{"key":"1206_CR52","unstructured":"Rexulti. Prescribing information. Otsuka Pharmaceutical Co; 2021."},{"key":"1206_CR53","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14656566.2023.2228686","volume":"24","author":"M H\u00f8jlund","year":"2023","unstructured":"H\u00f8jlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother. 2023;24:1463\u201389. https:\/\/doi.org\/10.1080\/14656566.2023.2228686.","journal-title":"Expert Opin Pharmacother"},{"key":"1206_CR54","volume-title":"Essential pharmacokinetics: a primer for pharmaceutical scientists","author":"T Loftsson","year":"2015","unstructured":"Loftsson T. Essential pharmacokinetics: a primer for pharmaceutical scientists. New York: Academic Press; 2015."},{"key":"1206_CR55","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.1038\/s41380-021-01267-y","volume":"26","author":"D Lupt\u00e1kov\u00e1","year":"2021","unstructured":"Lupt\u00e1kov\u00e1 D, Vallianatou T, Nilsson A, et al. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood\u2013brain barrier. Mol Psychiatry. 2021;26:7732\u201345.","journal-title":"Mol Psychiatry"},{"key":"1206_CR56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/17425255.2022.2147425","volume":"18","author":"CA Buzea","year":"2022","unstructured":"Buzea CA, Manu P, Dima L, Correll CU. Drug\u2013drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs. Expert Opin Drug Metab Toxicol. 2022;18:729\u201344. https:\/\/doi.org\/10.1080\/17425255.2022.2147425.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1206_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/17425255.2022.2086121","volume":"18","author":"CA Buzea","year":"2022","unstructured":"Buzea CA, Dima L, Correll CU, Manu P. Drug\u2013drug interactions involving antipsychotics and antihypertensives. Expert Opin Drug Metab Toxicol. 2022;18:285\u201398. https:\/\/doi.org\/10.1080\/17425255.2022.2086121.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1206_CR58","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2174\/138920010791636202","volume":"11","author":"J Sheehan","year":"2010","unstructured":"Sheehan J, Sliwa J, Amatniek J, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11:516\u201325. https:\/\/doi.org\/10.2174\/138920010791636202.","journal-title":"Curr Drug Metab"},{"key":"1206_CR59","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.apsb.2018.04.003","volume":"8","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B. 2018;8:721\u201332. https:\/\/doi.org\/10.1016\/j.apsb.2018.04.003.","journal-title":"Acta Pharm Sin B"},{"key":"1206_CR60","doi-asserted-by":"publisher","first-page":"42068","DOI":"10.4088\/JCP.22f14593","volume":"83","author":"C Andrade","year":"2022","unstructured":"Andrade C. Psychotropic drugs with long half-lives: implications for drug discontinuation, occasional missed doses, dosing interval, and pregnancy planning. J Clin Psychiatry. 2022;83:42068. https:\/\/doi.org\/10.4088\/JCP.22f14593.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR61","doi-asserted-by":"publisher","unstructured":"Correll CU, Jain R, Meyer JM, et al. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat. 2019;15:2537\u201350. https:\/\/doi.org\/10.2147\/NDT.S210340.","DOI":"10.2147\/NDT.S210340"},{"key":"1206_CR62","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/dddt.S95100","volume":"10","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Dev Ther. 2016;10:327\u201338. https:\/\/doi.org\/10.2147\/dddt.S95100.","journal-title":"Drug Des Dev Ther"},{"key":"1206_CR63","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/cts.12720","volume":"13","author":"A Periclou","year":"2020","unstructured":"Periclou A, Willavize S, Jaworowicz D, et al. Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania. Clin Transl Sci. 2020;13:362\u201371.","journal-title":"Clin Transl Sci"},{"key":"1206_CR64","doi-asserted-by":"publisher","unstructured":"Maxwell SR. Pharmacodynamics and pharmacokinetics for the prescriber. Medicine. 2023;52(1):1\u201310. https:\/\/doi.org\/10.1016\/j.mpmed.2023.10.008.","DOI":"10.1016\/j.mpmed.2023.10.008"},{"key":"1206_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"JA Lieberman","year":"2004","unstructured":"Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251\u201367. https:\/\/doi.org\/10.2165\/00023210-200418040-00005.","journal-title":"CNS Drugs"},{"key":"1206_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trens Neurosci. 2019;42:205\u201320.","journal-title":"Trens Neurosci"},{"key":"1206_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15\u201333. https:\/\/doi.org\/10.1002\/wps.20693.","journal-title":"World Psychiatry"},{"key":"1206_CR68","doi-asserted-by":"publisher","unstructured":"Kiss B, Kr\u00e1mos B, Laszlovszky I. Potential mechanisms for why not all antipsychotics are able to occupy dopamine D3 receptors in the brain in vivo. Front Psychiatry. 2022;13. https:\/\/doi.org\/10.3389\/fpsyt.2022.785592.","DOI":"10.3389\/fpsyt.2022.785592"},{"key":"1206_CR69","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","volume":"43","author":"SE Yohn","year":"2022","unstructured":"Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43:1098\u2013112. https:\/\/doi.org\/10.1016\/j.tips.2022.09.006.","journal-title":"Trends Pharmacol Sci"},{"key":"1206_CR70","first-page":"40","volume":"66","author":"LN Yatham","year":"2005","unstructured":"Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66:40\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00162","volume":"6","author":"O Stiedl","year":"2015","unstructured":"Stiedl O, Pappa E, Konradsson-Geuken \u00c5, \u00d6gren SO. The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. Front Pharmacol. 2015;6: 159078. https:\/\/doi.org\/10.3389\/fphar.2015.00162.","journal-title":"Front Pharmacol"},{"key":"1206_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14728222.10.4.515","volume":"10","author":"P Seeman","year":"2006","unstructured":"Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515\u201331. https:\/\/doi.org\/10.1517\/14728222.10.4.515.","journal-title":"Expert Opin Ther Targets"},{"key":"1206_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781946","volume":"12","author":"P Mohr","year":"2021","unstructured":"Mohr P, Masopust J, Kopecek M. Dopamine receptor partial agonists: do they differ in their clinical efficacy? Front Psychiatry. 2021;12: 781946. https:\/\/doi.org\/10.3389\/fpsyt.2021.781946.","journal-title":"Front Psychiatry"},{"key":"1206_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.12788\/cp.0203","volume":"21","author":"LL Citrome","year":"2022","unstructured":"Citrome LL. Olanzapine-samidorphan combination for schizophrenia or bipolar I disorder. Curr Psychiatry. 2022;21:35.","journal-title":"Curr Psychiatry"},{"key":"1206_CR75","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/schbul\/sbac144","volume":"49","author":"CU Correll","year":"2023","unstructured":"Correll CU, Stein E, Graham C, et al. Reduction in multiple cardiometabolic risk factors with combined olanzapine\/samidorphan compared with olanzapine: post hoc analyses from a 24-week phase 3 study. Schizophr Bull. 2023;49:454\u201363. https:\/\/doi.org\/10.1093\/schbul\/sbac144.","journal-title":"Schizophr Bull"},{"key":"1206_CR76","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","volume":"177","author":"CU Correll","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177:1168\u201378. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19121279.","journal-title":"Am J Psychiatry"},{"key":"1206_CR77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-013-0079-5","volume":"27","author":"A Cerovecki","year":"2013","unstructured":"Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27:545\u201372. https:\/\/doi.org\/10.1007\/s40263-013-0079-5.","journal-title":"CNS Drugs"},{"key":"1206_CR78","doi-asserted-by":"publisher","first-page":"16953","DOI":"10.4088\/jcp.v67n0122","volume":"67","author":"CU Correll","year":"2006","unstructured":"Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67:16953. https:\/\/doi.org\/10.4088\/jcp.v67n0122.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR79","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S2215-0366(22)00158-4","volume":"9","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry. 2022;9:614\u201324. https:\/\/doi.org\/10.1016\/S2215-0366(22)00158-4.","journal-title":"Lancet Psychiatry"},{"key":"1206_CR80","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40263-023-01009-4","volume":"37","author":"JM Rubio","year":"2023","unstructured":"Rubio JM, Guinart D, Kane JM, Correll CU. Early non-response to antipsychotic treatment in schizophrenia: a systematic review and meta-analysis of evidence-based management options. CNS Drugs. 2023;37:499\u2013512. https:\/\/doi.org\/10.1007\/s40263-023-01009-4.","journal-title":"CNS Drugs"},{"key":"1206_CR81","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hup.2247","volume":"27","author":"SD Targum","year":"2012","unstructured":"Targum SD, Pestreich L, Reksoprodjo P, et al. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. Hum Psychopharmacol. 2012;27:455\u201363. https:\/\/doi.org\/10.1002\/hup.2247.","journal-title":"Hum Psychopharmacol"},{"key":"1206_CR82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/pharmacy11050162","volume":"11","author":"ZS Qadir","year":"2023","unstructured":"Qadir ZS, Kar N, Ball PA, Morrissey H. Antipsychotic use: cross-sectional opinion survey of psychiatrists in India and United Kingdom. Pharmacy. 2023;11:162. https:\/\/doi.org\/10.3390\/pharmacy11050162.","journal-title":"Pharmacy"},{"key":"1206_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-244X-10-75","volume":"10","author":"AW Nyhuis","year":"2010","unstructured":"Nyhuis AW, Faries DE, Ascher-Svanum H, et al. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010;10:75. https:\/\/doi.org\/10.1186\/1471-244X-10-75.","journal-title":"BMC Psychiatry"},{"key":"1206_CR84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/2045125318754472","volume":"8","author":"K Hatta","year":"2018","unstructured":"Hatta K, Sugiyama N, Ito H. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy. Ther Adv Psychopharmacol. 2018;8:173\u201383. https:\/\/doi.org\/10.1177\/2045125318754472.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1206_CR85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/NDT.S294521","volume":"17","author":"X Liao","year":"2021","unstructured":"Liao X, Ye H, Si T. A review of switching strategies for patients with schizophrenia comorbid with metabolic syndrome or metabolic abnormalities. Neuropsychiatr Dis Treat. 2021;17:453\u201369. https:\/\/doi.org\/10.2147\/NDT.S294521.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR86","doi-asserted-by":"publisher","unstructured":"Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;CD006629. https:\/\/doi.org\/10.1002\/14651858.CD006629.pub2.","DOI":"10.1002\/14651858.CD006629.pub2"},{"key":"1206_CR87","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/schbul\/sbaa191","volume":"47","author":"D Siskind","year":"2021","unstructured":"Siskind D, Gallagher E, Winckel K, et al. Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis. Schizophr Bull. 2021;47:948\u201358. https:\/\/doi.org\/10.1093\/schbul\/sbaa191.","journal-title":"Schizophr Bull"},{"key":"1206_CR88","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","volume":"74","author":"JW Newcomer","year":"2013","unstructured":"Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry. 2013;74:1108\u201320. https:\/\/doi.org\/10.4088\/JCP.12028ah1.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR89","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/1039856218810166","volume":"26","author":"L Xu","year":"2018","unstructured":"Xu L, Krishnaswamy S. Switch-associated adverse events: focus on olanzapine. Australas Psychiatry. 2018;26:635\u20139. https:\/\/doi.org\/10.1177\/1039856218810166.","journal-title":"Australas Psychiatry"},{"key":"1206_CR90","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10488-023-01327-1","volume":"51","author":"K Richards","year":"2024","unstructured":"Richards K, Johnsrud M, Zacker C, Sasan\u00e9 R. One-year medication treatment patterns, healthcare resource utilization, and expenditures for Medicaid patients with schizophrenia starting oral atypical antipsychotic medication. Adm Policy Ment Health. 2024;51:207\u201316. https:\/\/doi.org\/10.1007\/s10488-023-01327-1.","journal-title":"Adm Policy Ment Health"},{"key":"1206_CR91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2017.08.012","volume":"193","author":"H Takeuchi","year":"2018","unstructured":"Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2018;193:29\u201336. https:\/\/doi.org\/10.1016\/j.schres.2017.08.012.","journal-title":"Schizophr Res"},{"key":"1206_CR92","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/pcn.13534","volume":"77","author":"H Takeuchi","year":"2023","unstructured":"Takeuchi H, Watabe K. Does short-term antipsychotic discontinuation of up to 3\u00a0weeks worsen symptoms in acute schizophrenia? A pooled analysis of placebo washout data. Psychiatry Clin Neurosci. 2023;77:338\u201344. https:\/\/doi.org\/10.1111\/pcn.13534.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1206_CR93","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/schbul\/sbw171","volume":"43","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Kantor N, Uchida H, et al. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull. 2017;43:862\u201371. https:\/\/doi.org\/10.1093\/schbul\/sbw171.","journal-title":"Schizophr Bull"},{"key":"1206_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2017.02.011","volume":"189","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: a meta-analysis. Schizophr Res. 2017;189:4\u20138. https:\/\/doi.org\/10.1016\/j.schres.2017.02.011.","journal-title":"Schizophr Res"},{"key":"1206_CR95","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1177\/0269881120922964","volume":"34","author":"H Takeuchi","year":"2020","unstructured":"Takeuchi H, Remington G. Immediate versus wait-and-gradual discontinuation in antipsychotic switching: a meta-analysis. J Psychopharmacol. 2020;34:914\u20139. https:\/\/doi.org\/10.1177\/0269881120922964.","journal-title":"J Psychopharmacol"},{"key":"1206_CR96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/13651501.2023.2231047","volume":"27","author":"P Baumann","year":"2023","unstructured":"Baumann P, Bauknecht P, Kuzin M, Schoretsanitis G. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. Int J Psychiatry Clin Pract. 2023;27:367\u201384. https:\/\/doi.org\/10.1080\/13651501.2023.2231047.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1206_CR97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/15622975.2015.1012225","volume":"17","author":"A Murru","year":"2016","unstructured":"Murru A, Hidalgo D, Bernardo M, et al. Antipsychotic switching in schizoaffective disorder: a systematic review. World J Biol Psychiatry. 2016;17:495\u2013513. https:\/\/doi.org\/10.3109\/15622975.2015.1012225.","journal-title":"World J Biol Psychiatry"},{"key":"1206_CR98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40801-023-00408-9","volume":"11","author":"C Patel","year":"2024","unstructured":"Patel C, Emont S, Cao Z, et al. Post hospitalization clinical quality outcomes among us patients with schizophrenia treated with a long-acting injectable or switched to a new oral antipsychotic: a retrospective cohort study. Drugs-Real World Outcomes. 2024;11:69\u201379. https:\/\/doi.org\/10.1007\/s40801-023-00408-9.","journal-title":"Drugs-Real World Outcomes"},{"key":"1206_CR99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12888-023-04558-6","volume":"23","author":"AJ Perkins","year":"2023","unstructured":"Perkins AJ, Khandker R, Overley A, et al. The impact of antipsychotic adherence on acute care utilization. BMC Psychiatry. 2023;23:64. https:\/\/doi.org\/10.1186\/s12888-023-04558-6.","journal-title":"BMC Psychiatry"},{"key":"1206_CR100","doi-asserted-by":"publisher","first-page":"371","DOI":"10.9758\/cpn.2016.14.4.371","volume":"14","author":"Y Kim","year":"2016","unstructured":"Kim Y, Wang S-M, Kwak K-P, et al. Amisulpride switching in schizophrenic patients who showed suboptimal effect and\/or tolerability to current antipsychotics in a naturalistic setting: an explorative study. Clin Psychopharmacol Neurosci. 2016;14:371. https:\/\/doi.org\/10.9758\/cpn.2016.14.4.371.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1206_CR101","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/NDT.S132363","volume":"13","author":"Y Liang","year":"2017","unstructured":"Liang Y, Yu X. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the escape study. Neuropsychiatr Dis Treat. 2017;13:1163\u201373. https:\/\/doi.org\/10.2147\/NDT.S132363.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR102","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/schbul\/sbac068","volume":"48","author":"S Heres","year":"2022","unstructured":"Heres S, Cordes J, Feyerabend S, et al. Changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia. Schizophr Bull. 2022;48:1273\u201383. https:\/\/doi.org\/10.1093\/schbul\/sbac068.","journal-title":"Schizophr Bull"},{"key":"1206_CR103","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/0269881111430748","volume":"26","author":"Y Chen","year":"2012","unstructured":"Chen Y, Bobo WV, Watts K, et al. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012;26:1201\u201310. https:\/\/doi.org\/10.1177\/0269881111430748.","journal-title":"J Psychopharmacol"},{"key":"1206_CR104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3371\/CSRP.5.2.3","volume":"5","author":"R Ganguli","year":"2011","unstructured":"Ganguli R, Brar J, Garbut R, et al. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses. 2011;5:75\u20139. https:\/\/doi.org\/10.3371\/CSRP.5.2.3.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"1206_CR105","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/JCP.0000000000000426","volume":"35","author":"T-J Hwang","year":"2015","unstructured":"Hwang T-J, Lo W-M, Chan H-Y, et al. Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics. J Clin Psychopharmacol. 2015;35:635\u201344. https:\/\/doi.org\/10.1097\/JCP.0000000000000426.","journal-title":"J Clin Psychopharmacol"},{"key":"1206_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-020-02957-7","volume":"20","author":"Y-W Jen","year":"2020","unstructured":"Jen Y-W, Hwang T-J, Chan H-Y, et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC Psychiatry. 2020;20:1\u201310. https:\/\/doi.org\/10.1186\/s12888-020-02957-7.","journal-title":"BMC Psychiatry"},{"key":"1206_CR107","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/YIC.0000000000000322","volume":"35","author":"N Kanahara","year":"2020","unstructured":"Kanahara N, Takase M, Sasaki T, et al. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Int Clin Psychopharmacol. 2020;35:338\u201344. https:\/\/doi.org\/10.1097\/YIC.0000000000000322.","journal-title":"Int Clin Psychopharmacol"},{"key":"1206_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4306\/pi.2010.7.3.189","volume":"7","author":"J-S Lee","year":"2010","unstructured":"Lee J-S, Chung S, Lee J-N, et al. Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics. Psychiatry Investig. 2010;7:189. https:\/\/doi.org\/10.4306\/pi.2010.7.3.189.","journal-title":"Psychiatry Investig"},{"key":"1206_CR109","doi-asserted-by":"publisher","first-page":"204512532110643","DOI":"10.1177\/20451253211064396","volume":"12","author":"CH Ma","year":"2022","unstructured":"Ma CH, Chan HY, Hsieh MH, et al. Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Ther Adv Psychopharmacol. 2022;12:20451253211064396. https:\/\/doi.org\/10.1177\/20451253211064396.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1206_CR110","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947\u201356. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111609.","journal-title":"Am J Psychiatry"},{"key":"1206_CR111","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.schres.2013.01.013","volume":"146","author":"TS Stroup","year":"2013","unstructured":"Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res. 2013;146:190\u20135. https:\/\/doi.org\/10.1016\/j.schres.2013.01.013.","journal-title":"Schizophr Res"},{"key":"1206_CR112","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pnpbp.2010.10.021","volume":"35","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Gen K, Inoue Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:161\u20138. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.10.021.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1206_CR113","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/NDT.S80925","volume":"11","author":"RA Wani","year":"2015","unstructured":"Wani RA, Dar MA, Chandel RK, et al. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat. 2015;11:685\u201393. https:\/\/doi.org\/10.2147\/NDT.S80925.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR114","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","volume":"39","author":"HW Yoon","year":"2016","unstructured":"Yoon HW, Lee JS, Park SJ, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol. 2016;39:288\u201394. https:\/\/doi.org\/10.1097\/WNF.0000000000000175.","journal-title":"Clin Neuropharmacol"},{"key":"1206_CR115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/hup.2366","volume":"29","author":"SN Roffeei","year":"2014","unstructured":"Roffeei SN, Reynolds GP, Zainal NZ, et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Hum Psychopharmacol. 2014;29:38\u201345. https:\/\/doi.org\/10.1002\/hup.2366.","journal-title":"Hum Psychopharmacol"},{"key":"1206_CR116","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","volume":"65","author":"CY Chen","year":"2011","unstructured":"Chen CY, Lin TY, Wang CC, Shuai HA. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci. 2011;65:95\u20137. https:\/\/doi.org\/10.1111\/j.1440-1819.2010.02156.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1206_CR117","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hup.2386","volume":"29","author":"I Miura","year":"2014","unstructured":"Miura I, Shiga T, Katsumi A, et al. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. Hum Psychopharmacol. 2014;29:199\u2013202. https:\/\/doi.org\/10.1002\/hup.2386.","journal-title":"Hum Psychopharmacol"},{"key":"1206_CR118","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1345\/aph.1Q700","volume":"46","author":"CS Wisniewski","year":"2012","unstructured":"Wisniewski CS, Robert S. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia. Ann Pharmacother. 2012;46:1097\u2013104. https:\/\/doi.org\/10.1345\/aph.1Q700.","journal-title":"Ann Pharmacother"},{"key":"1206_CR119","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/14656566.2015.1013029","volume":"16","author":"A Fagiolini","year":"2015","unstructured":"Fagiolini A, Brugnoli R, Di Sciascio G, et al. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother. 2015;16:727\u201337. https:\/\/doi.org\/10.1517\/14656566.2015.1013029.","journal-title":"Expert Opin Pharmacother"},{"key":"1206_CR120","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/2045125318772712","volume":"8","author":"B Veznedaroglu","year":"2018","unstructured":"Veznedaroglu B, Dilbaz N, Uzun O, Isik E. TARC: Turkish aripiprazole consensus report-aripiprazole use and switching from other antipsychotics to aripiprazole-consensus recommendations by a Turkish multidisciplinary panel. Ther Adv Psychopharmacol. 2018;8:271\u201385. https:\/\/doi.org\/10.1177\/2045125318772712.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1206_CR121","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S29891","volume":"8","author":"P Cazorla","year":"2012","unstructured":"Cazorla P, Mackle M, Zhao J, et al. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2012;8:247\u201357. https:\/\/doi.org\/10.2147\/NDT.S29891.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR122","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/npr2.12416","volume":"44","author":"K Nakagome","year":"2024","unstructured":"Nakagome K, Tachimori H, Endo S, et al. A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacol Rep. 2024;44:187\u201396. https:\/\/doi.org\/10.1002\/npr2.12416.","journal-title":"Neuropsychopharmacol Rep"},{"key":"1206_CR123","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/npr2.12107","volume":"40","author":"J Ishigooka","year":"2020","unstructured":"Ishigooka J, Usami T, Iwashita S, et al. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (secondary publication). Neuropsychopharmacol Rep. 2020;40:122\u20139. https:\/\/doi.org\/10.1002\/npr2.12107.","journal-title":"Neuropsychopharmacol Rep"},{"key":"1206_CR124","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1177\/02698811231177268","volume":"37","author":"F Yamasaki","year":"2023","unstructured":"Yamasaki F, Kanahara N, Nakata Y, et al. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. J Psychopharmacol. 2023;37:992\u20131002. https:\/\/doi.org\/10.1177\/02698811231177268.","journal-title":"J Psychopharmacol"},{"key":"1206_CR125","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1017\/S1092852918001086","volume":"24","author":"CU Correll","year":"2019","unstructured":"Correll CU, Shi L, Weiss C, et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians\u2019 choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019;24:507\u201317. https:\/\/doi.org\/10.1017\/S1092852918001086.","journal-title":"CNS Spectr"},{"key":"1206_CR126","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbv019","volume":"41","author":"S Leucht","year":"2015","unstructured":"Leucht S, Winter-van Rossum I, Heres S, et al. The optimization of treatment and management of schizophrenia in Europe (optimise) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41:549\u201358. https:\/\/doi.org\/10.1093\/schbul\/sbv019.","journal-title":"Schizophr Bull"},{"key":"1206_CR127","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, van Rossum IW, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (optimise): a three-phase switching study. Lancet Psychiatry. 2018;5:797\u2013807. https:\/\/doi.org\/10.1016\/S2215-0366(18)30252-9.","journal-title":"Lancet Psychiatry"},{"key":"1206_CR128","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/JCP.0000000000001804","volume":"44","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Misawa F, Takeuchi H. Real-world effectiveness of high-dose olanzapine and clozapine for treatment-resistant schizophrenia in Japan: a retrospective bidirectional mirror-image study. J Clin Psychopharmacol. 2024;44:151\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001804.","journal-title":"J Clin Psychopharmacol"},{"key":"1206_CR129","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4088\/JCP.15m10286","volume":"78","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Lee J, Fervaha G, et al. Switching to clozapine using immediate versus gradual antipsychotic discontinuation: a pilot, double-blind, randomized controlled trial. J Clin Psychiatry. 2017;78:223\u20138. https:\/\/doi.org\/10.4088\/JCP.15m10286.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR130","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15504263.2011.57011","volume":"7","author":"MF Brunette","year":"2011","unstructured":"Brunette MF, Dawson R, O\u2019Keefe CD, et al. A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011;7:50\u201363. https:\/\/doi.org\/10.1080\/15504263.2011.57011.","journal-title":"J Dual Diagn"},{"key":"1206_CR131","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.schres.2013.11.042","volume":"153","author":"PJ Weiden","year":"2014","unstructured":"Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153:160\u20138. https:\/\/doi.org\/10.1016\/j.schres.2013.11.042.","journal-title":"Schizophr Res"},{"key":"1206_CR132","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3371\/CSRP.CIWE.103114","volume":"8","author":"L Citrome","year":"2015","unstructured":"Citrome L, Weiden PJ, Alva G, et al. Switching to iloperidone: an omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8:183\u201395. https:\/\/doi.org\/10.3371\/CSRP.CIWE.103114.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"1206_CR133","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.schres.2020.12.006","volume":"228","author":"CU Correll","year":"2021","unstructured":"Correll CU, Vanover KE, Davis RE, et al. Safety and tolerability of lumateperone 42\u00a0mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res. 2021;228:198\u2013205. https:\/\/doi.org\/10.1016\/j.schres.2020.12.006.","journal-title":"Schizophr Res"},{"key":"1206_CR134","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4088\/JCP.12m07992","volume":"74","author":"JP McEvoy","year":"2013","unstructured":"McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74:170\u20139. https:\/\/doi.org\/10.4088\/JCP.12m07992.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-14-53","volume":"14","author":"G Awad","year":"2014","unstructured":"Awad G, Hassan M, Loebel A, et al. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC Psychiatry. 2014;14:1\u201310. https:\/\/doi.org\/10.1186\/1471-244X-14-53.","journal-title":"BMC Psychiatry"},{"issue":"20","key":"1206_CR136","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12888-020-02523-1","volume":"5","author":"GW Mattingly","year":"2020","unstructured":"Mattingly GW, Haddad PM, Tocco M, et al. Switching to lurasidone following 12\u00a0months of treatment with risperidone: results of a 6-month, open-label study. BMC Psychiatry. 2020;5(20):199. https:\/\/doi.org\/10.1186\/s12888-020-02523-1.","journal-title":"BMC Psychiatry"},{"key":"1206_CR137","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1017\/S109285291300093X","volume":"19","author":"L Citrome","year":"2014","unstructured":"Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014;19:330\u20139. https:\/\/doi.org\/10.1017\/S109285291300093X.","journal-title":"CNS Spectr"},{"key":"1206_CR138","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2014.07.015","volume":"158","author":"K Hatta","year":"2014","unstructured":"Hatta K, Otachi T, Fujita K, et al. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophr Res. 2014;158:213\u201322. https:\/\/doi.org\/10.1016\/j.schres.2014.07.015.","journal-title":"Schizophr Res"},{"key":"1206_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-12-218","volume":"12","author":"J Hong","year":"2012","unstructured":"Hong J, Novick D, Brugnoli R, et al. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. BMC Psychiatry. 2012;12:1\u20139. https:\/\/doi.org\/10.1186\/1471-244X-12-218.","journal-title":"BMC Psychiatry"},{"key":"1206_CR140","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.euroneuro.2013.04.010","volume":"23","author":"O Agid","year":"2013","unstructured":"Agid O, Schulze L, Arenovich T, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013;23:1017\u201322. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.04.010.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1206_CR141","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1185\/03007995.2013.869201","volume":"30","author":"WF Gattaz","year":"2014","unstructured":"Gattaz WF, de Oliveira Campos JA, Lacerda AL, et al. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Curr Med Res Opin. 2014;30(4):695\u2013709. https:\/\/doi.org\/10.1185\/03007995.2013.869201.","journal-title":"Curr Med Res Opin"},{"key":"1206_CR142","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","volume":"29","author":"EY Kim","year":"2013","unstructured":"Kim EY, Chang SM, Shim JC, et al. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Curr Med Res Opin. 2013;29:1231\u201340. https:\/\/doi.org\/10.1185\/03007995.2013.816277.","journal-title":"Curr Med Res Opin"},{"key":"1206_CR143","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013688","volume":"98","author":"TM Si","year":"2019","unstructured":"Si TM, Cai SL, Zhuo JM, Zhang LL. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: post hoc analysis of an open-label, prospective study. Medicine (Baltim). 2019;98: e13688. https:\/\/doi.org\/10.1097\/MD.0000000000013688.","journal-title":"Medicine (Baltim)"},{"key":"1206_CR144","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/NDT.S130483","volume":"13","author":"F Yang","year":"2017","unstructured":"Yang F, Li J, Tan YL, et al. Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication. Neuropsychiatr Dis Treat. 2017;13:1089\u201397. https:\/\/doi.org\/10.2147\/NDT.S130483.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1206_CR145","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0269881113516203","volume":"28","author":"DS Yang","year":"2014","unstructured":"Yang DS, Seong SJ, Yoon YR, et al. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. J Psychopharmacol. 2014;28:341\u20138. https:\/\/doi.org\/10.1177\/0269881113516203.","journal-title":"J Psychopharmacol"},{"key":"1206_CR146","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/pcn.12026","volume":"67","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Gen K, Otomo M, et al. Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. Psychiatry Clin Neurosci. 2013;67:76\u201382. https:\/\/doi.org\/10.1111\/pcn.12026.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1206_CR147","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13651501.2013.845218","volume":"18","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Gen K, Inoue Y, et al. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Int J Psychiatry Clin Pract. 2014;18:58\u201362. https:\/\/doi.org\/10.3109\/13651501.2013.845218.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1206_CR148","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1185\/03007995.2012.762903","volume":"29","author":"P Chue","year":"2013","unstructured":"Chue P, Malla A, Bouchard R-H, et al. The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Curr Med Res Opin. 2013;29:227\u201339. https:\/\/doi.org\/10.1185\/03007995.2012.762903.","journal-title":"Curr Med Res Opin"},{"key":"1206_CR149","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2045125313479127","volume":"3","author":"E Smeraldi","year":"2013","unstructured":"Smeraldi E, Cavallaro R, Folnegovic-Smalc V, et al. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre). Ther Adv Psychopharmacol. 2013;3:191\u20139. https:\/\/doi.org\/10.1177\/2045125313479127.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1206_CR150","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hup.2251","volume":"27","author":"I Miura","year":"2012","unstructured":"Miura I, Takeuchi S, Katsumi A, et al. Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. Hum Psychopharmacol. 2012;27:517\u201320. https:\/\/doi.org\/10.1002\/hup.2251.","journal-title":"Hum Psychopharmacol"},{"key":"1206_CR151","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/YIC.0b013e32834fc431","volume":"27","author":"M Fang","year":"2012","unstructured":"Fang M, Chen H, Li L, et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharmacol. 2012;27:107\u201313. https:\/\/doi.org\/10.1097\/YIC.0b013e32834fc431.","journal-title":"Int Clin Psychopharmacol"},{"key":"1206_CR152","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/pcn.12136","volume":"68","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Sugai T, Ono S, et al. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry Clin Neurosci. 2014;68:353\u20136. https:\/\/doi.org\/10.1111\/pcn.12136.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1206_CR153","first-page":"384","volume":"23","author":"I Popovic","year":"2011","unstructured":"Popovic I, Ravanic D, Popovic V, et al. First generation antipsychotics switch with risperidone in the treatment of chronic schizophrenic patients. Psychiatr Danub. 2011;23:384\u20138.","journal-title":"Psychiatr Danub"},{"key":"1206_CR154","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/01.pra.0000396061.05269.c8","volume":"17","author":"ON Karayal","year":"2011","unstructured":"Karayal ON, Glue P, Bachinsky M, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2011;17:100\u20139. https:\/\/doi.org\/10.1097\/01.pra.0000396061.05269.c8.","journal-title":"J Psychiatr Pract"},{"key":"1206_CR155","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2016.11.002","volume":"85","author":"HH Wang","year":"2017","unstructured":"Wang HH, Cai M, Wang HN, et al. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. J Psychiatr Res. 2017;85:59\u201365. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.11.002.","journal-title":"J Psychiatr Res"},{"key":"1206_CR156","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0032-1301884","volume":"45","author":"C Mencacci","year":"2012","unstructured":"Mencacci C, All I. Efficacy and tolerability of switching to ziprasidone in Italian patients with acute exacerbation of schizophrenia: an open-label trial. Pharmacopsychiatry. 2012;45:236\u201340. https:\/\/doi.org\/10.1055\/s-0032-1301884.","journal-title":"Pharmacopsychiatry"},{"key":"1206_CR157","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.pnpbp.2010.05.010","volume":"34","author":"E Stip","year":"2010","unstructured":"Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:997\u20131000. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.05.010.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1206_CR158","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.euroneuro.2018.06.005","volume":"28","author":"JP Bogers","year":"2018","unstructured":"Bogers JP, Schulte PF, Broekman TG, et al. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial. Eur Neuropsychopharmacol. 2018;28:1024\u201334. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.06.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1206_CR159","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00213-013-3012-1","volume":"228","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Graff-Guerrero A, Uchida H, et al. Dopamine D2\/3 occupancy of ziprasidone across a day: a within-subject pet study. Psychopharmacology. 2013;228:43\u201351. https:\/\/doi.org\/10.1007\/s00213-013-3012-1.","journal-title":"Psychopharmacology"},{"key":"1206_CR160","doi-asserted-by":"publisher","first-page":"39683","DOI":"10.4088\/JCP.SU21024IP1","volume":"83","author":"CU Correll","year":"2022","unstructured":"Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83:39683. https:\/\/doi.org\/10.4088\/JCP.SU21024IP1.","journal-title":"J Clin Psychiatry"},{"key":"1206_CR161","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-023-01022-7","volume":"37","author":"JM Meyer","year":"2023","unstructured":"Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS Drugs. 2023;37:545\u201370. https:\/\/doi.org\/10.1007\/s40263-023-01022-7.","journal-title":"CNS Drugs"},{"key":"1206_CR162","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/13543784.2022.2158811","volume":"31","author":"M H\u00f8jlund","year":"2022","unstructured":"H\u00f8jlund M, Correll CU. Ulotaront: a TAAR1\/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert Opin Investig Drugs. 2022;31:1279\u201390. https:\/\/doi.org\/10.1080\/13543784.2022.2158811.","journal-title":"Expert Opin Investig Drugs"},{"key":"1206_CR163","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamapsychiatry.2023.4353","volume":"81","author":"CU Correll","year":"2024","unstructured":"Correll CU, Citrome L. Pharmacologic treatment of schizophrenia beyond dopamine receptor blockade\u2014Has its time come yet? JAMA Psychiat. 2024;81:118\u201320. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4353.","journal-title":"JAMA Psychiat"},{"key":"1206_CR164","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","volume":"92","author":"N Fabiano","year":"2025","unstructured":"Fabiano N, Wong S, Zhou C, et al. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2025;92:62\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1206_CR165","unstructured":"Psychoactive drug screening program. http:\/\/pdsp.Med.Unc.Edu. Accessed 03 Mar 2010."},{"key":"1206_CR166","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1021\/jm401958n","volume":"57","author":"P Li","year":"2014","unstructured":"Li P, Zhang Q, Robichaud AJ, et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem. 2014;57:2670\u201382. https:\/\/doi.org\/10.1021\/jm401958n.","journal-title":"J Med Chem"},{"key":"1206_CR167","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang X-P, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119\u201328. https:\/\/doi.org\/10.1007\/s00213-009-1521-8.","journal-title":"Psychopharmacology"},{"key":"1206_CR168","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","volume":"32","author":"NM Richtand","year":"2007","unstructured":"Richtand NM, Welge JA, Logue AD, et al. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007;32:1715\u201326. https:\/\/doi.org\/10.1038\/sj.npp.1301305.","journal-title":"Neuropsychopharmacology"},{"key":"1206_CR169","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"NH Jensen","year":"2008","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, et al. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology. 2008;33:2303\u201312. https:\/\/doi.org\/10.1038\/sj.npp.1301646.","journal-title":"Neuropsychopharmacology"},{"key":"1206_CR170","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-McLeod","year":"2015","unstructured":"Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R&D. 2015;15:163\u201374. https:\/\/doi.org\/10.1007\/s40268-015-0092-x.","journal-title":"Drugs R&D"},{"key":"1206_CR171","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bmc.2011.12.019","volume":"20","author":"K Peprah","year":"2012","unstructured":"Peprah K, Zhu XY, Eyunni SV, et al. Multi-receptor drug design: haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem. 2012;20:1291\u20137. https:\/\/doi.org\/10.1016\/j.bmc.2011.12.019.","journal-title":"Bioorg Med Chem"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01206-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01206-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01206-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:01:40Z","timestamp":1757512900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01206-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":171,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01206-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"26 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The open access fee was funded by the German DEAL agreement. Intra-Cellular Therapies, Inc., a Johnson & Johson company, funded this study through an unrestricted educational grant. The sponsor had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.U. Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris, and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, IntraCellular Therapies, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Boehringer-Ingelheim, Janssen, and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u00a0approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Christoph U. Correll was involved in manuscript conception and design; read, critically reviewed, and revised the work; approved the final submitted manuscript, and agrees to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}